UALCAN

UALCAN is an interactive web resource for analyzing cancer data: University of ALabama CANcer data portal

Yes! You All CAN

[UALCAN @Now_UALCAN]

Preprint of our comprehensive breast cancer data analysis platform MammOnc-DB with over 20,000 breast cancer patient sample data (https://t.co/wLqMHEii5F…) is now online at: https://t.co/yped2fnB9k
@UABPathology, @UABHeersink, @theNCI, @NCIDataSci , @NCIgenomics , @BCRFAlabama

[UALCAN @Now_UALCAN]

UALCAN (https://t.co/ieIhO4mhUc) has been visited over 1.5 million times and cited over 6,000 times during last 8 years, enabling many discoveries. Thanks to collaborators and users for their kind support. @UABPathology, @UABHeersink, @theNCI, @NCIgenomics, @NCIDataSci, #Cancer

[UAB Pathology @UABPathology]

Thanks to the innovation of @uabpathology faculty @Varambally_S and @darshan_sc, cancer research is now mobile: The team has created a free mobile app based on their comprehensive cancer proteogenomic platform, @Now_UALCAN. https://t.co/nfzu0REQun

[UALCAN @Now_UALCAN]

UALCAN team is happy to release "UALCAN Mobile", a free app for analyzing #TCGA cancer gene expression data on the go. https://t.co/P1NB4LiKQB. @UABPathology, @ONealCancerUAB, @UABHeersink, @InformaticsUAB, @bcmhouston, #CancerResearch @NCIDataSci, @theNCI, @NCIgenomics

[UALCAN @Now_UALCAN]

UALCAN (https://t.co/ieIhO4mhUc) analysis show that PD-L1 and IDO1, regulators of immune responses and therapeutic targets are increased and co-expressed in subtype of bladder cancers. @BladderCancerUS, #CancerResearch, @NCIgenomics, @NCIDataSci, @UABPathology, #TCGA

[UALCAN @Now_UALCAN]

Our collaborative study "Global impact of somatic structural variation on the cancer proteome" is online @
https://t.co/4zNRC5OmD5
Proteomics data are deposited in UALCAN platform @ https://t.co/ieIhO4mhUc, @UABPathology,
@ONealCancerUAB, @UABHeersink, @bcmhouston, #Cancer

[UALCAN @Now_UALCAN]

A perspective on using cancer proteomics to identify targets was published with our collaborators.https://t.co/ZMAgLTtsnW. The cancer data analysis platform UALCAN, https://t.co/P1NB4LiKQB provides the Clinical Proteomic Tumor Analysis Consortium data
@UABPathology, #Cancer

[UALCAN @Now_UALCAN]

Updates to UALCAN (https://t.co/P1NB4LiKQB), the comprehensive cancer "Omics" data analysis platform was presented at
@AACR Annual meeting today at Orlando.
@UABPathology, @ONealCancerUAB, @UABHeersink, @darshan_sc, @Varambally_S , @DrNetto , @NCIDataSci, @NCIgenomics, #Cancer

[UALCAN @Now_UALCAN]

UALCAN (https://t.co/ieIhO4mhUc) tops 1 million visits. https://t.co/Mrs6f2L7IZ
@theNCI , @NCIgenomics, @Americancancer, #TCGA, #CPTAC, #Cancer, #CancerResearch

[Soory Varambally @Varambally_S]

We had a cake cutting to celebrate "Million" site visit for comprehensive #cancer data analysis platform UALCAN (https://t.co/lJno3XDONP) at the @UABPathology department research retreat today.
@DrNetto, @darshan_sc

[UALCAN @Now_UALCAN]

We are extremely honored to note that we (https://t.co/ieIhO4mhUc) reached the landmark of a “Million” site visits. @UABPathology, @ONealCancerUAB, @InformaticsUAB, @UABHeersink, @bcmhouston, @NCIgenomics, @NCIDataSci, @AmericanCancer, #Cancer, #teamwork

[UALCAN @Now_UALCAN]

Received a kind note today "Thank you for developing UALCAN. I don't think my day goes by without visiting it at least once. UALCAN is extensively used in industries developing drug targets". Purpose is served when discoveries are made and #Cancer targets identified
@NCIgenomics

[Soory Varambally @Varambally_S]

Our first study on EZH2 in cancer, published in Nature (2002) reached 3,000 citations today (2022). Many exciting investigations have been done on it during the last 20 years in various cancers and diseases now. It has got FDA approved inhibitor as well. #Cancer.

[UALCAN @Now_UALCAN]

UALCAN (https://t.co/ieIhO448G4) now provides list of potential #Cancer prognostic markers with Kaplan–Meier curves at :https://t.co/3u4rf8ZyU2
@UABPathology, @NCIDataSci , @NCIgenomics, @ONealCancerUAB, @UABHeersink, @bcmhouston, @ACS_Research.

[UALCAN @Now_UALCAN]

UALCAN (https://t.co/ieIhO4lK4E), the integrative cancer data analysis portal reached 3,000 citations. We are thankful to all the users and suggestions @UABPathology, @ONealCancerUAB, @UABHeersink, @InformaticsUAB, @NCIgenomics, @NCIDataSci, @bcmhouston, #Cancer, Yes! You All Can

[UALCAN @Now_UALCAN]

@RaisBahrami @Varambally_S @sonpavde @DrNetto @UABHeersink @ONealCancerUAB @UABPathology @BladderCancerUS @UABUrology @JedUro1 @uabprecisionmed @Umanne Thanks Soroush, @JedUro1 put great thoughts and efforts in to this.

[UALCAN @Now_UALCAN]

Our study "ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors". Appeared in JCI Insight.
https://t.co/pFnXfR4aub

@JedUro1, @sonpavde, @DrNetto, @UABHeersink,
@ONealCancerUAB, @UABPathology,
@UABUrology, @darshan_sc, #Cancer

[UALCAN @Now_UALCAN]

Thrilled to see kind words for comprehensive and user-friendly #cancer data analysis portal, UALCAN (https://t.co/ieIhO448G4) from experts like Dr. Bradner! @UABPathology, @UABHeersink, @InformaticsUAB, @ONealCancerUAB, @NCIgenomics, @NCIDataSci, @NCIResearchCtr, @NCICancerCtrl

[UALCAN @Now_UALCAN]

Our new manuscript "Proteogenomic characterization of 2002 cancers" is online at Nature Communication
https://t.co/eiFb3MJfv3. Data is integrated in to UALCAN (https://t.co/ieIhO448G4). @UABPathology, @ONealCancerUAB, @UABHeersink, @NCIDataSci,
@NCIgenomics, @bcmhouston, #Cancer

[UALCAN @Now_UALCAN]

UALCAN (https://t.co/ieIhO448G4) now provides compendium of mass spectrometry-based proteomics data of over 2000 tumors, molecular subtypes and associated pathways @UABPathology, @ONealCancerUAB, @UABHeersink, @bcmhouston, @NCIDataSci, @NCIgenomics,@UMICH, #Cancer, #TCGA, #CPTAC